Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, highlighting significant pipeline advancements for its lead candidates Halneuron and SP16, which address the urgent need for non-opioid pain treatments.
The company has enrolled 164 patients in its Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP), with top-line results expected in fall 2026. Halneuron, a NaV 1.7 inhibitor, has received fast track designation from the FDA for CINP. Additionally, SP16, an LRP1 agonist, received IND approval from the FDA and will begin enrollment in mid-2026 for chemotherapy-induced pain and peripheral neuropathy (CIPPN). The Phase 1b trial is fully funded by the National Cancer Institute and will be conducted at the University of Virginia.
“Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress for both Halneuron, with Phase 2b data anticipated this fall, and SP16, which received FDA clearance to progress into Phase 1b development this quarter,” said Greg Duncan, CEO of Dogwood Therapeutics. “Furthermore, we executed a global development license for our legacy combination antiviral assets.”
Financially, the company completed a financing of up to $26.9 million in January 2026, with $12.5 million in gross proceeds received. Cash on hand totaled $13.2 million as of March 31, 2026, providing operational runway into the fourth quarter of 2026. Research and development expenses were $2.7 million for Q1 2026, compared to $2.4 million in Q1 2025, driven by increased drug development costs for Halneuron and personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to higher salaries and personnel costs. Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to $12.2 million, or $8.45 per share, in the prior-year period, reflecting reduced non-cash charges.
The company’s pipeline includes Halneuron, a non-opioid analgesic targeting NaV 1.7, and SP16 IV, which acts as an LRP1 agonist to provide anti-inflammatory and neuroprotective effects. SP16 has shown preclinical potential to reduce IL-6, IL-8, IL1B, and TNF-alpha levels, as well as to repair damaged tissue via increases in pAKT and pERK. The forthcoming Phase 1b CIPPN trial is fully funded by the National Cancer Institute.
Dogwood Therapeutics is a development-stage biopharmaceutical company focused on first-in-class non-opioid medicines for pain and neuropathic disorders. Its largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange. For more information, visit www.dwtx.com.
